» Articles » PMID: 34696321

The Not-So-Good, the Bad and the Ugly: HPV E5, E6 and E7 Oncoproteins in the Orchestration of Carcinogenesis

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2021 Oct 26
PMID 34696321
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Infection with HPV starts with the access of the viral particles to basal cells in the epidermis, potentially via microtraumas to the skin. The basal cells are able to keep away these pathogens in normal circumstances through a robust immune response from the host, as HPV infections are, in general, cleared within 2 to 3 weeks. However, the rare instances of persistent infection and/or in cases where the host immune system is compromised are major risk factors for the development of lesions potentially leading to malignancy. Evolutionarily, obligatory pathogens such as HPVs would not be expected to risk exposing the host to lethal cancer, as this would entail challenging their own life cycle, but infection with these viruses is highly correlated with cancer and malignancy-as in cancer of the cervix, which is almost always associated with these viruses. Despite this key associative cause and the availability of very effective vaccines against these viruses, therapeutic interventions against HPV-induced cancers are still a challenge, indicating the need for focused translational research. In this review, we will consider the key roles that the viral proteins play in driving the host cells to carcinogenesis, mainly focusing on events orchestrated by early proteins E5, E6 and E7-the not-so-good, the bad and the ugly-and discuss and summarize the major events that lead to these viruses mechanistically corrupting cellular homeostasis, giving rise to cancer and malignancy.

Citing Articles

Virus-mediated immunosuppression in head and neck cancer.

Miyauchi S, Roy S, Boutros N, Sharabi A Oncogene. 2025; .

PMID: 40074885 DOI: 10.1038/s41388-025-03295-2.


Risk factors for pelvic lymph node metastasis in cervical cancer: a retrospective analysis of 186 patients.

Sun X, He L, Wang S Front Oncol. 2025; 15:1525946.

PMID: 39959672 PMC: 11825327. DOI: 10.3389/fonc.2025.1525946.


Sexually transmitted human papillomavirus and related sequelae.

Hanft W, Stankiewicz Karita H, Khorsandi N, Vohra P, Plotzker R Clin Microbiol Rev. 2025; 38(1):e0008523.

PMID: 39950806 PMC: 11905373. DOI: 10.1128/cmr.00085-23.


Methylation sites of human papillomavirus 16 as potential biomarkers for cervical cancer progression.

Ji S, Ji N Front Oncol. 2025; 15:1481621.

PMID: 39931088 PMC: 11807812. DOI: 10.3389/fonc.2025.1481621.


E6AP is essential for the proliferation of HPV-positive cancer cells by preventing senescence.

Avenhaus A, Velimirovic M, Bulkescher J, Scheffner M, Hoppe-Seyler F, Hoppe-Seyler K PLoS Pathog. 2025; 21(2):e1012914.

PMID: 39919145 PMC: 11805377. DOI: 10.1371/journal.ppat.1012914.


References
1.
Jones D, Thompson D, Munger K . Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology. 1998; 239(1):97-107. DOI: 10.1006/viro.1997.8851. View

2.
James C, Roberts S . Viral Interactions with PDZ Domain-Containing Proteins-An Oncogenic Trait?. Pathogens. 2016; 5(1). PMC: 4810129. DOI: 10.3390/pathogens5010008. View

3.
DeMasi J, Huh K, Nakatani Y, Munger K, Howley P . Bovine papillomavirus E7 transformation function correlates with cellular p600 protein binding. Proc Natl Acad Sci U S A. 2005; 102(32):11486-91. PMC: 1182553. DOI: 10.1073/pnas.0505322102. View

4.
Barrow-Laing L, Chen W, Roman A . Low- and high-risk human papillomavirus E7 proteins regulate p130 differently. Virology. 2010; 400(2):233-9. PMC: 2861914. DOI: 10.1016/j.virol.2010.01.034. View

5.
Gardiol D, Kuhne C, Glaunsinger B, Lee S, Javier R, Banks L . Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene. 1999; 18(40):5487-96. DOI: 10.1038/sj.onc.1202920. View